Clinical Trial of Teriparatide in Japan

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Japanese women with primary osteoporosis

• Postmenopausal women aged at least 55 years

• Patients with a high risk for fracture

Exclusion Criteria:

• History of metabolic bone disorders other than osteoporosis

• History of any secondary causes of osteoporosis

• History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated

• Severe or chronically disabling conditions other than osteoporosis